Browsing by Author Dutriaux, Caroline

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2017Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaKefford, Richard (Rick); Long, Georgina; Atkinson, Victoria; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Hauschild, Axel; Haydon, Andrew; Larkin, J; MandalĂ , Mario; Nyakas, Marta; Santinami, Mario; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicineAdjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma, New England Journal of Medicine, vol.377, 19, 2017,pp 1813-1823
2017Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialLong, Georgina; Arance, A; Ascierto, Paolo A; Del Vecchio, M; Di Giacomo, A; Dummer, R; Dutriaux, Caroline; et al, Various; Gutzmer, R.; Rutkowski, Piotr; Schadendorf, D; Northern Clinical School: MedicineBinimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial, The Lancet Oncology, vol.18, 4, 2017,pp 435-445
2015Nivolumab in Previously Untreated Melanoma without BRAF MutationLong, Georgina; Brady, Ben; Dutriaux, Caroline; et al, Various; Hassel, Jessica; Hernberg, Micaela; Kalinka-Warzocha, Ewa; Maio, Michele; McNeil, Catriona; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Savage, Kerry; Central Clinical School: The Sydney Cancer CentreNivolumab in Previously Untreated Melanoma without BRAF Mutation, The New England Journal of Medicine, vol.372, 4, 2015,pp 320-330
2017Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsLong, Georgina; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Garbe, Claus; Hauschild, Axel; Karaszewska, Boguslawa; Levchenko, Evgeny; Schachter, Jacob; Schadendorf, D; Stroiakovski, Daniel; Northern Clinical School: MedicineThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials, European Journal of Cancer, vol.82, N/A, 2017,pp 45-55